CurrentCapital BluecrossPolicy AHS - G2150 - Biomarkers for Myocardial Infarction and Chronic Heart Failure, 1 = Initial Presentation

Biomarkers for Myocardial Infarction and Chronic Heart Failure

Coverage policy for laboratory measurement of cardiac biomarkers (e.g., troponin, BNP/NT‑proBNP, CK‑MB, AST, LDH, myoglobin, ST2 and others) for diagnosis and management of myocardial infarction and heart failure; applies to Capital BlueCross members as specified by benefit coverage and applicable state/federal rules.

Policy Summary

PayerCapital Bluecross

PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure

Policy CodePolicy AHS - G2150 - Biomarkers for Myocardial Infarction and Chronic Heart Failure, 1 = Initial Presentation

Change TypeNo material change noted

Effective DateApr 19, 2018

Next Review DateN/A

Key ActionDocument serial troponin measurements (presentation and repeat sampling) and record relation to the 99th percentile URL when diagnosing myocardial infarction.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 4troponin tests permitted within first 72 hours

up to 4/yrBNP/NT‑proBNP outpatient frequency

6+biomarkers not covered for MI diagnosis

2018→2025

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

96%sites using troponin primary biomarker

Coverage Criteria — Cardiac Biomarkers

inv-01: Troponin testing — Initial presentation

Covered when the listed conditions are met:

Troponin for suspected ACS: For individuals presenting with signs and symptoms of acute coronary syndrome, quantitative measurement of cardiac troponin (T or I) for diagnosis of myocardial infarction meets coverage criteria up to four times within the first 72 hours following initial presentation.<=4 tests within 72 hours

Outpatient facility must be capable of performing an adequate clinical MI evaluation.

inv-02: BNP/NT‑proBNP testing

Covered when ANY of the following are met:

BNP/NT‑proBNP uses: Measurement of B-type natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP) to diagnose heart failure in individuals presenting with dyspnea or to establish disease severity in individuals with chronic heart failure.<=4 per year for chronic HF outpatient

Interpret as part of a complete clinical assessment; age-dependent thresholds apply.

inv-03: Not Medically Necessary / Not Covered

Not covered (explicit):

Not covered biomarkers for ACS: For individuals presenting with signs and symptoms of acute coronary syndrome, measurement of AST (SGOT), CK, CK‑MB, CK isoenzymes, LD/LDH, myoglobin, copeptin, troponin C, C‑reactive protein, H‑FABP, and any other cardiac biomarkers not listed as covered DOES NOT MEET COVERAGE CRITERIA.

Qualitative troponin measurement in an outpatient setting also does not meet coverage criteria.

ST2 in outpatient setting: Analysis of ST2 and/or its isoforms (e.g., Presage ST2) in the outpatient setting does not meet coverage criteria.

inv-04: MI diagnostic biomarker criteria

Diagnosis of acute myocardial infarction when biomarker evidence is used:

Universal Definition criteria: A rising and/or falling pattern of cardiac troponin levels AND at least one troponin measurement greater than the 99th percentile of the upper reference limit (URL).99th percentile

High-sensitivity cTn assays are recommended for routine use (Fourth Universal Definition).

CK-MB alternative: If a cardiac troponin assay is unavailable, CK‑MB may be used as the best alternative; CK‑MB above the 99th percentile of the URL can be used as the decision level for MI (use sex-specific values).99th percentile

CK‑MB is less sensitive and specific than troponin.

inv-05: ACS biomarker timing and sampling

Initial evaluation of patients with suspected acute coronary syndrome (ACS):

Timing and serial measurement: Measure troponin at presentation and again 3–6 hours after symptom onset in all patients presenting with ACS symptoms; identify rising/falling patterns. If symptom onset is unclear, use time of presentation as time zero.3-6 hours

Re-measure beyond 6 hours if clinical or ECG findings suggest ACS despite normal early troponins.

inv-06: Heart failure biomarker use

Measurement of BNP or NT-proBNP for patients with dyspnea or at risk of HF:

Diagnostic support for HF: Measure natriuretic peptides (BNP or NT‑proBNP) in patients presenting with dyspnea to help establish or exclude heart failure; interpret results as part of a full clinical assessment.age-dependent; NT-proBNP >900 pg/mL approx equals BNP >100 pg/mL

Serial measurements may have prognostic value; ADA recommends consideration of screening in adults with diabetes to detect stage B HF.

inv-07: Prognostic and adjunct biomarker criteria

Use of novel biomarkers for prognosis and risk stratification:

sST2 prognostic use: sST2 measurement (e.g., Presage assay) can assist prognostic assessment in chronic heart failure and certain post-transplant settings; higher sST2 levels are associated with worse outcomes.study-specific cutoffs reported (e.g., >36.3 ng/mL, ~34.99 ng/mL, ~43.43 ng/mL)

Presage ST2 assay is FDA-cleared as an aid in assessing prognosis of chronic HF; evidence is prognostic rather than diagnostic.

H-FABP and copeptin have shown early diagnostic potential in some studies but are not recommended as replacements for troponin; evidence is mixed and they are not primary recommended biomarkers for MI diagnosis.early hours after symptom onset

Use as adjuncts only; routine standalone use is not encouraged.

inv-08: Troponin measurement in suspected ACS

Guideline-based indications and timing for troponin measurement in suspected ACS

Troponin for diagnosis of MI: Measure cardiac-specific troponin (I or T) at presentation and 3–6 hours after symptom onset in all patients with suspected ACS to identify rising/falling patterns.presentation and 3–6 hours (or sampling per local hs assay guidance)

If symptom onset is ambiguous, use time of presentation as time zero; obtain additional troponin beyond 6 hours if indicated by ECG/clinical features.

Early rule-out with high-sensitivity assays (NICE guidance): When using high-sensitivity cardiac troponin assays, an initial sample with a repeat at 30 minutes to 3 hours may be used for earlier rule-out; thresholds near the assay limit of detection or the 99th percentile should be applied according to the chosen protocol.30 min–3 h repeat; 99th percentile or limit-of-detection thresholds

hs-cTn zero/2h strategies require concurrent clinical risk stratification.

inv-09: Natriuretic peptides in heart failure

Use of natriuretic peptides in heart failure

BNP/NT-proBNP for diagnosis and prognosis in HF: Measure BNP or NT‑proBNP to support diagnosis or exclusion of heart failure in patients presenting with dyspnea and to establish prognosis in chronic or acutely decompensated HF.not specified numerically in these excerpts

Serial biomarker-guided therapy to direct treatment lacks sufficient evidence for routine use to reduce hospitalizations or mortality.

inv-10: Periprocedural MI criteria (SCAI)

Definition of clinically relevant MI post-revascularization per SCAI

SCAI thresholds for periprocedural MI: For patients with normal baseline CK‑MB: peak CK‑MB within 48 hours >10× the laboratory ULN, or >5× ULN with new pathologic Q‑waves in >2 contiguous leads or new persistent LBBB; if CK‑MB not available and baseline cTn normal, cTn within 48 hours rises to >70× ULN, or >35× ULN with qualifying ECG changes. For elevated baseline biomarkers, require absolute increments per the same multiples and consideration of biomarker stability.CK‑MB >10× ULN (or >5× with Q‑waves/LBBB); cTn >70× ULN (or >35× with Q‑waves/LBBB)

SCAI prefers CK‑MB if available but includes cTn when CK‑MB is not available.

Qualitative measurement of cardiac troponin (troponin T or I) performed in an outpatient setting (for example, an independent laboratory or physician office) does not meet coverage criteria and may be denied. The policy also explicitly lists several older or non‑preferred biomarkers — including AST (SGOT), CK, CK‑MB, CK isoenzymes, LD/LDH, and myoglobin — as not meeting coverage criteria for diagnosis or prognosis of acute coronary syndrome (ACS). These exclusions reflect the preference for quantitative, guideline‑recommended troponin testing and adherence to benefit coverage and applicable state/federal rules when ordering biomarker assays.

The 2014 AHA/ACC guideline for management of NSTE‑ACS recommends using cardiac troponin (I or T) for diagnosis of myocardial infarction and explicitly states that CK‑MB and myoglobin should not be used for diagnosis of ACS when troponin assays are available. The guideline calls for troponin measurement at presentation and again 3–6 hours after symptom onset and emphasizes identifying a rising and/or falling pattern.

The American Society for Clinical Pathology (ASCP) recommends against using CK‑MB or myoglobin to diagnose acute myocardial infarction and instead endorses testing with troponin I or T, noting troponins' cardiac specificity and supporting reliance on troponin assays.

The 2018 NICE recommendations for chronic heart failure do not include measurement of ST2 for diagnosing chronic HF. NICE recommends measuring NT‑proBNP in people with suspected heart failure, and ST2 is not mentioned as a diagnostic test in the chronic HF guidance.

Analysis of ST2 (including soluble ST2/Presage ST2) in the outpatient setting does not meet coverage criteria. The policy lists outpatient ST2 testing among assays considered not medically necessary due to insufficient published evidence to support diagnostic or therapeutic benefit.

Heart‑type fatty acid binding protein (H‑FABP) and copeptin have shown early diagnostic potential in some studies, but evidence is inconsistent and they are not recommended as replacements for troponin. The policy states H‑FABP and copeptin are generally not encouraged as primary diagnostic tests because troponins are superior.

Routine use of serial BNP or NT‑proBNP measurements to guide therapy is not supported by consistent evidence of improved mortality or reduced hospitalizations. Guideline reviews note that although reductions in natriuretic peptide levels have been associated with better outcomes, there are insufficient data to recommend routine biomarker‑guided therapy using serial BNP/NT‑proBNP measurements.

Procedure Codes, Thresholds, and Diagnostic Thresholds

Applicable CPT/HCPCS procedure codesmixed

No codes listed

Procedure codes citedCPT

82550	Creatine kinase (CK), (CPK); total
82552	Creatine kinase (CK), (CPK); isoenzymes
82553	Creatine kinase (CK), (CPK); MB fraction only
82554	Creatine kinase (CK), (CPK); isoforms
82725	Fatty acids, nonesterified
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)
83615	Lactate dehydrogenase (LD), (LDH)
83625	Lactate dehydrogenase (LD), (LDH); isoenzymes, separation and quantitation
83874	Myoglobin
83880	Natriuretic peptide

1–10 of 17

1/2

Troponin diagnostic threshold — Universal Definition

Troponin diagnostic thresholdAt least one cardiac troponin measurement greater than the 99th percentile of the assay upper reference limit (URL)

Assay typesUse cardiac-specific troponin I or T (high-sensitivity assays recommended for routine use)

Pattern requirementDiagnosis requires a rising and/or falling pattern in troponin values in addition to a value >99th percentile

NT-proBNP / BNP equivalence

NT-proBNP equivalenceNT-proBNP >900 pg/mL is roughly equivalent to BNP >100 pg/mL

Clinical useMeasure NT-proBNP to help diagnose or exclude heart failure in patients presenting with dyspnea

Provider Actions, Documentation, and Authorization Notes

Prior Authorization

Prior Authorization and Coverage Verification

Follow individual benefit coverage and applicable government program rules (Medicare/Medicaid). Verification of member benefits is required prior to testing. Coverage may be denied for tests listed as DOES NOT MEET COVERAGE CRITERIA, including use of non‑recommended biomarkers in the outpatient setting.

Benefit verification required — coverage depends on individual benefits and applicable government program rules (LCD/NCD/State Medicaid take precedence).
Non‑covered biomarkers: AST, CK, CK‑MB, CK isoenzymes, LDH, myoglobin, copeptin, troponin C, CRP, H‑FABP, ST2 (outpatient), and any other biomarkers listed as DOES NOT MEET COVERAGE CRITERIA.
Qualitative troponin assays in outpatient settings are explicitly not covered.
Laboratory‑Developed Tests (LDTs) are regulated under CLIA; FDA clearance is not required for clinical use but labs must validate LDTs.

Documentation Required

Documentation Requirements for Troponin Testing and MI Diagnosis

Background and Context

Cardiac biomarkers are released into the bloodstream after myocardial injury and are used across acute and chronic clinical contexts. Troponins (I or T) are the preferred markers for diagnosing myocardial infarction and for early rule‑out/rule‑in strategies; BNP and NT‑proBNP are used to support diagnosis and assess severity of heart failure. Older biomarkers such as CK‑MB, AST, LDH, and myoglobin have limited specificity compared with troponin and are generally discouraged when contemporary troponin assays are available.

Definitions and Key Terms

Cardiac biomarkers — definition and examples

DefinitionCardiac biomarkers are biochemical markers released into blood from injured myocardial tissue used for diagnosis and risk stratification in acute and chronic settings

ExamplesCommon examples include cardiac troponin (I or T), CK‑MB, B‑type natriuretic peptide (BNP) / NT‑proBNP, and soluble ST2 (sST2)

Clinical rolesTroponins: preferred for MI diagnosis; BNP/NT‑proBNP: used to diagnose/exclude and stratify heart failure; sST2: prognostic adjunct in chronic HF

Acute coronary syndrome (ACS)

Definition of ACSAcute coronary syndrome (ACS) encompasses a spectrum from angina and reversible injury to unstable angina and myocardial infarction, subdivided by ECG findings into STEMI and NSTEMI

Clinical presentation

Policy Summary

PayerCapital Bluecross

PolicyBiomarkers for Myocardial Infarction and Chronic Heart Failure

Policy CodePolicy AHS - G2150 - Biomarkers for Myocardial Infarction and Chronic Heart Failure, 1 = Initial Presentation

Change TypeNo material change noted

Effective DateApr 19, 2018

Next Review DateN/A

Key ActionDocument serial troponin measurements (presentation and repeat sampling) and record relation to the 99th percentile URL when diagnosing myocardial infarction.

SourceLink

On This Page

Interpretation noteInterpret natriuretic peptide results as part of the full clinical assessment; thresholds vary with age

ST2 prognostic threshold (tertile)

ST2 prognostic tertileHighest sST2 tertile >36.3 ng/mL associated with markedly increased risk (hazard ratio reported) in chronic heart failure cohorts

Complementary biomarkersST2 used alongside NT-proBNP to modestly improve prognostic assessment beyond clinical risk scores

Assay examplePresage ST2 assay is the commonly used commercial method (FDA-cleared for prognostic use)

sST2 mortality-associated cutoffs (study-specific)

Study-specific sST2 cutoffsReported mortality-associated cutoffs include ~34.99 ng/mL and 43.43 ng/mL (study-derived optimal thresholds)

Prognostic performanceCutoff ~43.43 ng/mL associated with higher all-cause mortality and moderate AUC (example study: Hou et al.)

Incremental riskRisk of death increases per ng/mL of sST2 after adjustment for covariates and NT-proBNP

Troponin sampling interval (NICE hs-troponin)

NICE hs-troponin sampling intervalWhen using high-sensitivity troponin assays, obtain an initial sample at presentation and repeat the sample 30 minutes to 3 hours later

Threshold guidanceUse 99th percentile thresholds or thresholds at/near the assay limit of detection depending on protocol

Rule-out vs rule-inThresholds near the limit of detection may be used for early rule-out but are not for rule-in of NSTEMI

SCAI post-revascularization biomarker thresholds

SCAI periprocedural MI thresholds (CK-MB)Peak CK-MB within 48 hours >10× local laboratory ULN, or >5× ULN with new pathologic Q‑waves in ≥2 contiguous leads or new persistent LBBB

SCAI periprocedural MI thresholds (cTn)If CK‑MB unavailable and baseline cTn normal: cTn within 48 hours rises to >70× ULN, or >35× ULN with qualifying ECG changes

Elevated baseline strategyWhen baseline biomarkers are elevated, require absolute increments equal to the stated multiples from the most recent preprocedure level

Troponin threshold — rule-out and rule-in

Rule-out vs rule-in troponin thresholdsUse troponin values at or near the assay limit of detection for early rule-out strategies; use the 99th percentile of the URL for rule-in/diagnosis of myocardial infarction

Assay selectionHigh-sensitivity troponin assays are preferred because of greater sensitivity and ability to use early sampling strategies

Documentation requirementWhen diagnosing MI, document a rise/fall pattern and at least one value above the 99th percentile plus supporting clinical criteria (symptoms, ECG, imaging, or angiographic thrombus)

Document clinical findings and sampling details when performing troponin testing for suspected myocardial infarction. Adherence to recommended sampling intervals, diagnostic thresholds, and demonstration of a rise and/or fall pattern is required to support medical necessity.

Required clinical documentation: record symptom onset time (or time of presentation if onset unclear), clinical signs/symptoms of ischemia, ECG findings, and any imaging or angiography results supporting ischemia.
Troponin sampling and threshold adherence: document assay type (high‑sensitivity vs contemporary), sample times for serial measurements, numeric troponin values, and use of the 99th percentile upper reference limit (or assay‑specific threshold/limit of detection per NICE when applicable).
Serial measurement and interpretation: document rise and/or fall pattern with at least one value above the 99th percentile to diagnose MI; if initial troponins are normal but clinical suspicion remains, repeat testing beyond six hours may be required per guideline recommendations.
When high‑sensitivity assays are used, note whether recommended early rule‑out protocols (e.g., 0 and 1–3 hour sampling depending on assay) were followed.

Denial Risk

Use of Non‑recommended Biomarkers and Preferred Assays

Use troponin I or T (preferably high‑sensitivity assays) as first‑line biomarkers for MI evaluation. Avoid use of CK‑MB, myoglobin, and other non‑recommended biomarkers for diagnosis of acute coronary syndrome unless no troponin assay is available; use of these non‑recommended tests may lead to denial.

Preferred sequencing: high‑sensitivity troponin assays preferred for routine clinical use; contemporary troponin assays acceptable when high‑sensitivity not available.
CK‑MB: consider only as an alternative when no troponin assay is available; CK‑MB is less sensitive and specific.
Non‑recommended biomarkers (AST, CK, CK‑MB, myoglobin, LDH, H‑FABP, copeptin, troponin C, CRP, ST2 in outpatient) are considered not meeting coverage criteria and their use may result in claim denial.

Step Therapy

Step Therapy and Prior Authorization Notes

There are no step‑therapy requirements specified in this policy for biomarker testing. Prior authorization is not detailed in the policy; follow individual benefit rules and payer prior authorization processes if applicable.

No step therapy requirements described.
Prior authorization: not specified in policy — follow benefit rules and payer-specific authorization processes.

Billing Rule

Billing/Coding and Denial Risks

Procedure codes listed in the policy are provided for reference; inclusion does not imply coverage. Tests listed under DOES NOT MEET COVERAGE CRITERIA may be denied. Ensure documentation supports medical necessity when billing the covered troponin and natriuretic peptide tests.

Key codes: 84484 (Troponin, quantitative), 84512 (Troponin, qualitative) — qualitative troponin in outpatient not covered; 83880 (Natriuretic peptide), 83006 (ST2) — ST2 not covered in outpatient for diagnosis of HF.
Unlisted/other codes (e.g., 84999) should be supported with full clinical documentation.
Inadequate documentation (failure to show rise/fall pattern or lack of values above 99th percentile when claiming MI) may result in denial.

Note

References and Policy Precedence

This section contains bibliographic references and does not itself create additional prior authorization triggers. When conflicts arise between this policy and government coverage (LCD/NCD/state Medicaid), the government policy prevails.

Bibliography includes ESC, AHA/ACC, NICE and other society guidelines that inform clinical expectations and documentation standards.
No specific authorization or denial triggers are contained solely within the references section.

Patients usually present with chest pain and associated signs/symptoms; ECG categorizes STEMI vs NSTEMI/unstable angina

Diagnostic elementsDiagnosis incorporates symptoms, ECG changes, imaging, and cardiac biomarker rise/fall patterns per universal definitions

CK‑MB — definition and role

CK‑MB definitionCreatine kinase MB (CK‑MB) is a cardiac-associated CK isoenzyme historically used for MI diagnosis but less sensitive and specific than troponin

KineticsTotal CK activity rises 3–9 hours after MI, peaks at 10–20 hours, and returns to normal by ~72 hours

Current roleCK‑MB may be used if troponin unavailable, but troponin is now the recommended test for MI diagnosis

High-sensitivity troponin (hs-cTn)

hs‑cTn definitionHigh-sensitivity cardiac troponin (hs‑cTn) assays detect lower troponin concentrations with greater analytical sensitivity, enabling earlier rule‑out/rule‑in strategies

Clinical advantageshs‑cTn allows earlier detection and higher negative predictive value; recommended by multiple guidelines for routine use

Testing strategyhs‑cTn strategies may use limits of detection for early rule‑out and 99th percentile for diagnosis, with repeat sampling per protocol (eg 30 min–3 h)

BNP / NT‑proBNP — definition and clinical use

BNP / NT‑proBNP definitionB‑type natriuretic peptide (BNP) and NT‑proBNP are peptides released from ventricular myocardium used to evaluate and prognosticate heart failure

Clinical useMeasure BNP/NT‑proBNP in patients presenting with dyspnea to help establish or exclude HF; useful for prognosis in chronic and acute HF

Threshold exampleNT‑proBNP >900 pg/mL approximates BNP >100 pg/mL; age-dependent optimal cutoffs exist

sST2 — definition and prognostic role

sST2 definitionSoluble ST2 (sST2) is a member of the IL‑1 receptor family released in response to cardiomyocyte stress and fibrosis; measured commercially by the Presage assay

Prognostic rolesST2 provides prognostic information in chronic heart failure and when combined with NT‑proBNP modestly improves risk stratification

Commercial assay and clearancePresage ST2 assay (Critical Diagnostics) is FDA‑cleared as an aid in assessing prognosis of chronic heart failure

High-sensitivity cardiac troponin — assay features & guidance

Contemporary hs‑cTn characteristicsHigh‑sensitivity cardiac troponin assays detect lower concentrations with improved negative predictive value and enable earlier clinical decision‑making

Guideline recommendationMultiple guidelines (Universal Definition, ESC, NICE, ACC/AHA) recommend hs‑cTn for routine use in MI evaluation

Operational guidanceInterpretation commonly uses the 99th percentile for diagnosis and limits of detection for early rule‑out; sampling intervals vary by protocol

SCAI clinically relevant MI after revascularization

SCAI clinically relevant MI definitionClinically relevant MI after revascularization defined by large multiples of ULN: e.g., CK‑MB >10× ULN (or >5× with new Q‑waves/LBBB) or cTn >70× ULN (or >35× with new Q‑waves/LBBB)

Preference and alternativesSCAI prefers CK‑MB if available but includes cTn criteria when CK‑MB is not available

Baseline elevation handlingFor elevated baseline biomarkers, require absolute increments equivalent to the stated multiples from the most recent preprocedure level

Myocardial infarction (MI) — NICE / Universal definition

MI per NICE/Universal definitionDiagnosis requires detection of a rise and/or fall of cardiac biomarkers (preferably troponin) with at least one value above the 99th percentile of the URL and ≥1 clinical criterion (symptoms, ECG changes, imaging, or intracoronary thrombus)

Preferred biomarkerCardiac troponin (I or T) is preferred for MI diagnosis; CK‑MB is an alternative if troponin unavailable

DocumentationDocument timing, assay type, serial values, and supporting clinical evidence when using biomarkers for MI diagnosis

High‑sensitivity troponin — sensitivity and NICE recommendations

hs‑cTn sensitivity enabling earlier detectionHigh‑sensitivity troponin assays provide greater sensitivity and negative predictive value, allowing earlier rule‑out/rule‑in decisions compared with conventional assays

NICE recommended assaysNICE lists multiple approved hs‑cTn assays for early rule‑out strategies and provides assay‑specific threshold guidance

Sampling & thresholdsNICE recommends initial and repeat sampling (30 minutes–3 hours) using thresholds at the limit of detection for rule‑out and 99th percentile for rule‑in when appropriate

Guideline and consensus references

Guideline sources citedKey references include ESC, NICE, AHA/ACC, ASCP and society position statements listed in the evidence references

Representative citationsReferences include ESC guidelines (2019–2024), NICE guidance on troponin and HF, and ASCP Choosing Wisely statements

PurposeThese guideline and consensus documents form the evidentiary basis for assay recommendations, thresholds, and sampling strategies in the policy